AR and prostate cancer: HDAC6 regulates androgen receptor hypersensitivity and nuclear localization by regulating Hsp90 acetylation in castration-resistant prostate cancer, and targeting HDAC6 or in combination with other therapeutic approaches is a promising new strategy for the prevention and/or treatment of castration-resistant prostate cancer (Ai et al. 2009).